An authorized generic of Depo-Medrol was sold before, but it isn’t sold now. Ask your pharmacist whether a regular generic (methylprednisolone acetate) is available.
Source: FDA, updated October 30, 2026
How to pay the least
Ask for the cash price
Generic methylprednisolone
No pharmacy we check posts a price for it.
- Ask your pharmacy for the cash price of generic methylprednisolone.Find pharmacies near you
- Ask one or two other pharmacies too. Cash prices for the same generic can differ a lot from store to store.
A regular generic has the same active ingredient as Depo-Medrol, and the FDA requires it to work the same way.
Compare every option
Question
Brand nameDepo-Medrol
Authorized genericmethylprednisolone
Regular genericmethylprednisolone
What you’d pay
Cash priceAsk the pharmacyUsually the highest price
Not soldNo longer sold
Cash priceAsk the pharmacyUsually the lowest
Same as Depo-Medrol?
The original
–
Same active ingredientFillers and dyes can differ
Details for each option
Details for
Brand nameNo maker’s card
We didn’t find a savings card or cash price from Depo-Medrol’s maker. Ask the pharmacy for Depo-Medrol’s cash price. With insurance, ask what your plan charges.
Authorized genericNot sold now
Regular genericWho makes it
3 companies sell a generic of Depo-Medrol that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
-
Amneal Pharmaceuticals40 mg/mL, 80 mg/mL
How it looks, what’s in it, NDCs
40 mg/mL White
Package NDC Carton of 1 mL 60219-1573-1 Carton of 25 mL 60219-1573-5 40 mg/mL White to off white
Package NDC Carton of 1 mL 70121-1573-1 Carton of 25 mL 70121-1573-5 40 mg/mL White to off white
Package NDC Carton of 10 mL 70121-1609-1 Carton of 250 mL 70121-1609-5 80 mg/mL White
Package NDC Carton of 1 mL 60219-1574-1 Carton of 25 mL 60219-1574-5 80 mg/mL White
Package NDC Carton of 1 mL 70121-1552-1 Carton of 25 mL 70121-1552-5 80 mg/mL White to off white
Package NDC Carton of 1 mL 70121-1574-1 Carton of 25 mL 70121-1574-5 80 mg/mL White to off white
Package NDC Carton of 5 mL 70121-1610-1 Carton of 125 mL 70121-1610-5 Inactive ingredients: hydrochloric acid, miripirium chloride, polyethylene glycol 3350, sodium chloride, sodium hydroxide, benzyl alcohol, polysorbate 80, sodium phosphate, dibasic, sodium phosphate, monobasic, water
-
Eugia40 mg/mL
How it looks, what’s in it, NDCs
40 mg/mL
Package NDC Carton of 10 mL 55150-313-01 Carton of 250 mL 55150-313-25 Inactive ingredients: polyethylene glycol 3350, polysorbate 80, sodium phosphate, monobasic, sodium phosphate, dibasic, benzyl alcohol, sodium chloride, sodium hydroxide, hydrochloric acid
-
Sagent Pharmaceuticals40 mg/mL, 80 mg/mL
Product page on sagentpharma.com
How it looks, what’s in it, NDCs
40 mg/mL
Package NDC Carton of 5 mL 25021-820-05 Carton of 10 mL 25021-820-10 80 mg/mL
Package NDC Carton of 5 mL 25021-821-05 Inactive ingredients: polyethylene glycol 3350, polysorbate 80, sodium phosphate, monobasic form, sodium phosphate, dibasic, benzyl alcohol, sodium chloride, sodium hydroxide, hydrochloric acid
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
What it’s used for
- Arthritis and gout flare-ups
- Bursitis and tendon inflammation
- Severe allergies and asthma
- Skin diseases
- Lupus and inflammatory muscle diseases
- Crohn’s disease (regional enteritis) and ulcerative colitis
- Blood disorders, leukemia and lymphoma
- Low adrenal hormones (adrenal insufficiency)
What the FDA label says
A. FOR INTRAMUSCULAR ADMINISTRATION
When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows:
Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Neoplastic Diseases: For palliative management of leukemias and lymphomas.
Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION
(see WARNINGS)
DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
C. FOR INTRALESIONAL ADMINISTRATION
DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
Source: the FDA label for Depo-Medrol (Pharmacia & Upjohn Company LLC), January 21, 2026. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/depo-medrol/